Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CD | O00329 | 13/20 | 0.37 |
| ▸ | FADS1 | O60427 | 2/20 | 0.36 |
| ▸ | PIK3R1 | P27986 | 7/20 | 0.35 |
| ▸ | PIK3CB | P42338 | 7/20 | 0.35 |
| ▸ | PIK3CG | P48736 | 7/20 | 0.35 |
| ▸ | CYP11B1 | P15538 | 2/20 | 0.33 |
| ▸ | CYP11B2 | P19099 | 2/20 | 0.33 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.33 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.33 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.33 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.33 |
| ▸ | GPR139 | Q6DWJ6 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL890505 | 0.87 | PIK3CD (0.38) | PIK3CDFADS1PIK3R1PIK3CBPIK3CG | |
| SCHEMBL890605 | 0.79 | PIK3CD (0.37) | PIK3CDFADS1PIK3R1PIK3CBPIK3CG | |
| SCHEMBL3098056 | 0.77 | KDM4E (0.45) | PIK3CDRXFP1 | |
| SCHEMBL890587 | 0.76 | PIK3CD (0.58) | PIK3CDFADS1PIK3R1PIK3CBPIK3CG | |
| SCHEMBL890508 | 0.76 | PIK3CD (0.58) | PIK3CDFADS1PIK3R1PIK3CBPIK3CG | |
| SCHEMBL3093843 | 0.75 | PIK3CD (0.35) | PIK3CDFADS1PIK3R1PIK3CBPIK3CG | |
| SCHEMBL10119944 | 0.73 | PIK3CD (0.34) | PIK3CDFADS1PIK3R1PIK3CBPIK3CG | |
| SCHEMBL23456485 | 0.72 | FADS1 (0.51) | FADS1CYP11B1CYP11B2GABRA1GABRB2 | |
| SCHEMBL890482 | 0.72 | FADS1 (0.38) | FADS1CYP11B1CYP11B2GABRA1GABRB2 | |
| SCHEMBL2504442 | 0.72 | PIK3CD (0.55) | PIK3CDPIK3R1PIK3CBPIK3CGCYP11B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7799795-B2 | Aryl nitrile compounds and compositions and their uses in treating inflammatory and related disorders | AMGEN INC. (US) | 2010-09-21 | — | — | US | disclosed |
| US-7799795-B2 | Aryl nitrile compounds and compositions and their uses in treating inflammatory and related disorders | AMGEN INC. (US) | 2010-09-21 | — | — | US | disclosed |
| US-7799795-B2 | Aryl nitrile compounds and compositions and their uses in treating inflammatory and related disorders | AMGEN INC. (US) | 2010-09-21 | — | — | US | disclosed |
| EP-1917250-B1 | ANTI-INFLAMMATORY ARYL NITRILE COMPOUNDS | AMGEN INC (US) | 2010-07-21 | — | — | EP | disclosed |
| EP-1917250-B1 | ANTI-INFLAMMATORY ARYL NITRILE COMPOUNDS | AMGEN INC (US) | 2010-07-21 | — | — | EP | disclosed |
| EP-1917250-A2 | ANTI-INFLAMMATORY ARYL NITRILE COMPOUNDS | Amgen, Inc (US) | 2008-05-07 | — | — | EP | disclosed |
| US-20070015773-A1 | Aryl nitrile compounds and compositions and their uses in treating inflammatory and related disorders | AMGEN INC. | 2007-01-18 | — | — | US | disclosed |
| US-20070015773-A1 | Aryl nitrile compounds and compositions and their uses in treating inflammatory and related disorders | AMGEN INC. | 2007-01-18 | — | — | US | disclosed |
| US-20070015773-A1 | Aryl nitrile compounds and compositions and their uses in treating inflammatory and related disorders | AMGEN INC. | 2007-01-18 | — | — | US | disclosed |
| WO-2007002701-A2 | ANTI-INFLAMMATORY ARYL NITRILE COMPOUNDS | AMGEN INC. (US) | 2007-01-04 | — | — | WO | disclosed |
| WO-2007002701-A2 | ANTI-INFLAMMATORY ARYL NITRILE COMPOUNDS | AMGEN INC. (US) | 2007-01-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070015773-A1 | Aryl nitrile compounds and compositions and their uses in treating inflammatory and related disorders | CCR1, MSR1, CCR2 | PIK3CD 2877/4885FADS1 2084/4885PIK3R1 2103/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.